Hemogenyx Pharmaceuticals outlines significant progress with HEMO-CAR-T in 2023 : vimarsana.com

Hemogenyx Pharmaceuticals PLC (LSE:HEMO, OTC:HOPHF) CEO Dr Vladislav Sandler tells Proactive's Stephen Gunnion that 2023 was a significant year for the...

Related Keywords

Stephen Gunnion , Vladislav Sandler , Drug Administration , Hemogenyx Pharmaceuticals , Investigational New Drug , Prevail Infoworks , Chimeric Bait Receptor ,